Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Bicycle Therapeutics plcNASDAQ: BCYC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $60.83M (cash outflow) fell 0.3% year over year, behind the +7.2% change in trailing-twelve-month net income. Sequentially, it rose 205.3% from the prior quarter. Over 3 fiscal years it compounded at +24.8% a year.
Context
- Net income amounted to 301.7% of revenue in FY2025, down 177.5 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$157.67M (-28.0%) for the fiscal year ending Dec 2026, a slowdown from the +29.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$60.83M+205.3% QoQ
- Last fiscal yearDec 2025
- -$218.96M+29.5% YoY
- LTMMar 2026
- -$218.8M+7.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.3% | -49.0% | -48.7 pp |
| 1 year | +29.5% | -28.0% | -57.5 pp |
| 3-year CAGR | +24.8% | -2.9% | -27.7 pp |
| 5-year CAGR | -14.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (218.96M) USD
- Year-over-year change
- -29.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (218.96M) | -29.5% |
| FY2024 | 2024-12-31 | (169.03M) | +6.4% |
| FY2023 | 2023-12-31 | (180.66M) | -60.3% |
| FY2022 | 2022-12-31 | (112.72M) | -68.7% |
| FY2021 | 2021-12-31 | (66.82M) | — |
Net Income vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's LTM Mar 2026 net income of $218.8M is the 2nd largest of the 10 companies compared; the peer median is $136.99M.
- Its year-over-year change of +7.2% is the 5th highest of 9, against a peer median of +7.4%.
- Net income amounts to 344.6% of revenue for BCYC, versus a peer median of 177.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $218.8M | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $151.18M | +37.1% | +27.8% | 260.9% | |
| LTM Dec 2025 | $138.44M | — | — | 119.4% | |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $76.12M | +14824.7% | -12.0% | — | |
| LTM Mar 2026 | $68.17M | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding BCYC) | $136.99M | +7.4% | +3.0% | 177.7% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.17M | 6.42M |
| Deferred Income Tax | (1.67M) | (4.98M) | 3.31M | (5.23M) | (850K) |
| Stock-Based Compensation | 12.08M | 26.78M | 32.48M | 38.08M | 39.46M |
| Change in Working Capital | 38.07M | 672K | 76.66M | (33.46M) | (75.75M) |
| Accounts Receivables | 4.54M | (11.35M) | (1.2M) | (11.95M) | 2.89M |
| Inventory | (4.79M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 2.56M | 8M | 3.1M | (6.87M) |
| Other Working Capital | 37.12M | 9.46M | 69.86M | (24.61M) | (71.77M) |
| Other Non-Cash Items | 2.14M | 442K | 1.04M | (2.26M) | 0 |
| Operating Cash Flow | (14.79M) | (86.11M) | (60.63M) | (164.72M) | (249.68M) |
| Capital Expenditures | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 5.49K |
| Investing Cash Flow | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.35M) |
| Debt Repayment | 15M | 0 | 0 | (31.91M) | 0 |
| Common Stock Issued | 298.54M | 5.7M | 249.35M | 544.13M | 37.09K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.18M | 989K | 682K | 7.53M | (168.09K) |
| Financing Cash Flow | 320.73M | 6.69M | 250.03M | 519.75M | (131K) |
| Effect of Forex Changes | (1.21M) | (1.12M) | 1.35M | (694K) | 804K |
| Net Change in Cash | 302.69M | (99.53M) | 187.82M | 353.1M | (251.35M) |
| Free Cash Flow | (16.82M) | (105.1M) | (63.56M) | (165.96M) | (252.61M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.